Roche cancer drug gets grim prognosis

Avastin, the top drug of Swiss pharmaceutical company Roche, may lose its approval for treating breast cancer in the United States.

This content was published on December 16, 2010 - 21:34 and agencies

As the world’s best-selling cancer medicine, Avastin has been approved for treating a variety of cancers. However, it failed to extend lives in four trials involving breast cancer patients.

"Given the number of serious and life-threatening side effects, the FDA does not believe there is a favourable risk-to-benefit ratio," Dr Richard Pazdur, the US Food and Drug Administration's head of cancer drugs, told reporters on Thursday.

Some side effects include holes in the stomach and intestines plus bleeding and blood clots.

Roche says that these problems occurred in less than four per cent of patients in the trials. The Basel-based company plans to request a hearing to contest the US decision. In the meantime, Avastin will retain its FDA approval.

In the wake of the news, analysts estimate that the Roche Group could lose as much as $1 billion (SFr0.97 billion) of its $6 billion in annual sales.

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?